ARTICLE | Product Development
Novavax secures $4M from CEPI for COVID-19 vaccine
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 10, 2020 8:10 PM UTC
Updated on Mar 25, 2020 at 7:09 PM UTC
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide $4 million to Novavax to fund development of a COVID-19 vaccine program.
Novavax Inc. (NASDAQ:NVAX) is developing a recombinant nanoparticle vaccine. The CEPI funding will cover some costs of preparing for a Phase I trial, CEPI and Novavax said...